Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate Effect on Hepatitis B Vaccine Response
NCT02057263Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis B (HBV) comparing Alendronate + Hep B Vaccine with Placebo + Hep B Vaccine (2 arms). Primary endpoints: Quantitative anti-HB surface IgG antibody titers at Month 6 and Safety/Adverse events at 5 months. Started Apr 2014; status: completed.
02
Drugs
alendronate
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02057263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057263.